Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

On the differential hemodynamic effects of prostacyclins and sotatercept.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026

Same author

Determining the individualized probability of myocardial recovery: The multicenter RecoverHeart calculator.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026

Same author

Cardiac Arrest From Sulfur Hexafluoride Contrast Anaphylaxis After Prior Perflutren Hypersensitivity.

JACC. Case reports·2026

Same author

Patient-Centered Outcomes in Heart Failure Pharmacotherapy: A Meta-Analysis of Randomized Controlled Trials.

JACC. Advances·2025

Same author

Mechano-Ino-Chronotropic Unloading in Cardiogenic Shock Due to Acute Myocardial Infarction-Hemodynamic Insights From Simulation Modeling.

Journal of the Society for Cardiovascular Angiography & Interventions·2025

Same author

The Advanced Heart Failure Workforce Crisis: A Path Forward.

Journal of cardiac failure·2025

Search research articles

Related Experiment Videos

Aldosterone antagonists in heart failure.

Maya Guglin¹, Olga Kristof-Kuteyeva, Irina Novotorova

¹University of South Florida, Tampa, FL 33647, USA. mguglin@gmail.com

Journal of Cardiovascular Pharmacology and Therapeutics

|December 17, 2010

Summary

This summary is machine-generated.

Aldosterone antagonists are effective for heart failure but underused due to hyperkalemia fears. Careful patient selection is crucial for safe and effective use of these heart failure medications.

Related Experiment Videos

Area of Science:

Cardiology
Pharmacology

Background:

Aldosterone antagonists, including spironolactone and eplerenone, are approved for symptomatic heart failure with reduced ejection fraction.
These drugs exhibit cardioprotective, antifibrotic, and antiarrhythmic properties demonstrated in preclinical and clinical studies.

Purpose of the Study:

To highlight the underutilization of aldosterone antagonists in heart failure management.
To emphasize the importance of patient selection for mitigating risks, primarily hyperkalemia.

Main Methods:

Review of existing randomized clinical trials and animal experiments on aldosterone antagonists.
Discussion of clinical practice guidelines and evidence regarding hyperkalemia risk management.

Main Results:

Aldosterone antagonists have proven benefits in reducing morbidity and mortality in heart failure patients.
Fear of hyperkalemia is a significant barrier to the widespread prescription of these medications.

Conclusions:

Optimizing the use of aldosterone antagonists requires meticulous patient screening and selection.
Further research and ongoing trials may expand indications to milder heart failure or preserved systolic function.